Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
What the clinical data has reported: Phase 2 trials of Retatrutide (Jastreboff et al., NEJM 2023, and follow-ups) reported: - Dose-dependent body weight reduction across 24- and 48-week dosing intervals - Reductions in liver fat content measured by MRI-proton density fat fraction (MRI-PDFF) in populations with metabolic dysfunction-associated steatotic liver disease (MASLD) - Glycaemic marker improvement (HbA1c, fasting glucose) in type 2 diabetes cohorts - Dose-related gastrointestinal adverse effects consistent with the GLP-1/GIP class nausea, vomiting, diarrhoea Important: these are clinical trial findings in regulated patient populations
you can't un-cook it
From GLP-1s to Insulin: What to Know About Peptides Peptides promise health benefits, but do they actually work
With high relapse and overdose rates across substances, novel therapeutic strategies are urgently needed
